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Abstract
Background: An on-site, rapid, fingertip, whole-blood point-of-care test (POCT) is attractive for active case-finding of coeliac
disease (CD) in primary care because of its simplicity.
Aim: The aim of this article is to assess the usefulness and cost-effectiveness of adult case-finding using a POCT based on
deamidated gliadin peptide antibodies (IgA/IgG-DGP) in primary care for CD diagnosis.
Methods: A case-finding study for CD was conducted by using an easy-to-use, on-site, whole-blood for IgA/IgG-DGP-based
fingertip POCT compared with tTG2 in 350 individuals. Sample size was calculated based on 0.28% prevalence in the
reference population. Duodenal biopsies for histology, intraepithelial lymphocytes and in situ deposition of tTG2 were
obtained if tTG2 and/or POCT were positive. Accuracy and cost-effectiveness of strategies using serology or POCT were
calculated.
Results: Prevalence of CD was 1.14% (95% CI, 0.3–3.4), almost double what was previously observed. Four patients were
diagnosed with CD. tTG2 was positive in three (0.85%) and POCT in 29 (8.2%). Sensitivity of POCT for CD was 100%,
specificity 93%, PPV 14%, and NPV 100%. POCT followed by duodenal biopsy was the most cost-effective approach in our
setting (standard diagnosis: E13,033/case; POCTþduodenal biopsy: E7360/case).
Conclusions: A negative POCT allows ruling out CD in primary care, making it suitable for case-finding. POCT strategy was
the most cost effective.
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Established knowledge on this subject
. Active case-finding is useful to detect new coeliac disease (CD) patients in primary care.
. Standard serology has been used for CD case-finding.
. A rapid point-of-care test (POCT) based on deamidated gliadin peptide antibodies (immunoglobulin
(Ig)A/IgG-DGP) was shown to be cost effective at pre-endoscopy in patients assessed with anaemia.
What are the significant and/or new findings of this study?
. A point-of-care test (POCT) based on immunoglobulin (Ig)A/IgG deamidated gliadin peptide (DGP) has
never been used as a diagnostic screening tool in a case-finding strategy in primary care, compared to
standard serology.
. A POCT based on IgA/IgG-DGP detection was demonstrated to be suitable for coeliac disease (CD)
screening in primary care identifying all seropositive CD patients while a negative test ruled out CD.
. The economic impact of this strategy has never been evaluated in this setting and showed to be cost
effective compared with the standard approach using serology.
Introduction
The prevalence of coeliac disease (CD) using serological
mass screening is around 0.2% to 1%1–4 but the
number of CD patients diagnosed in clinical practice
is much lower and CD remains under-diagnosed.
Active case-finding is useful in terms of an increase in
the number of newly detected CD patients in primary
care.5–9 This approach relies on an active role being
played by primary care physicians (PCPs) in selecting
the individuals to be tested for CD. Standard serology
(endomysial (AEA) or anti-transglutaminase 2 antibo-
dies (tTG2)) has generally been used for this purpose.10
In symptomatic patients the prevalence of CD is higher
than in the general population, ranging from 2% to
10%.5–9 A number of studies have demonstrated that
CD-related complications are reversed by a gluten-
free diet (GFD). Thus, case-finding has to be
encouraged.11,12
An easy-to-use, on-site, whole-blood, deamidated
gliadin peptide (DGP)-based, fingertip, point-of-care
test (POCT) provides rapid results,13 making it particu-
larly attractive for use in primary care. The Simtomax
assay detects CD with a combination of immunoglobu-
lin A (IgA) and immunoglobulin G (IgG) antibodies
against DGP, allowing the detection of CD in IgA-defi-
cient patients. It has been recently demonstrated that
Simtomax has a similar accuracy to standard serology
for biopsy-proven CD and is more reliable than
another commercially available POCT based on
tTG2.14
The costs of different diagnostic approaches applied
to large populations may be highly variable, having an
impact on the public health system. A recent study
demonstrated that the performance of a POCT
(Simtomax-IgA/IgG-DGP) pre-endoscopy in patients
assessed with anaemia was cost effective.15
The aims were to assess: (a) the effectiveness of a
strategy of adult case-finding using a POCT in primary
care for CD diagnosis compared with serology, and
(b) whether this strategy was cost effective.
Patients and methods
A cross-sectional study was carried out in the health
area of the Hospital Universitari Mutua Terrassa,
from April 2014 to September 2015. Three primary
care centres (PCCs) providing health assistance to
100,000 inhabitants participated in the study. The first
step consisted in setting up an educational programme
designed to go beyond updated notions on CD. All 58
PCPs of the three PCCs were invited to complete a pre-
study questionnaire to assess their knowledge about
CD. Thirty-four of them (58.6%) chose to participate.
Consecutive adult patients following a gluten-
containing diet with clinical manifestations of CD
were included (Table 1).
Study procedures
POCT (Symtomax) and tTG2 testing were conducted
in parallel on patients meeting the enrolment criteria.
Individuals with positive POCT and/or tTG2 testing
were referred for duodenal biopsy to assess histopath-
ology, intraepithelial lymphocyte (IEL) flow cytometry,
and in situ deposition of tTG2 antibodies. A blood
sample was obtained for confirmatory tTG2 and
AEA and CD genetic markers (human leucocyte anti-
gen (HLA)-DQ2.5, HLA-DQ2.2, and/or HLA-DQ8).
Patients with negative POCT and standard serology
but with persistent severe symptoms were also referred
for duodenal biopsy (Figure 1). A detailed description
of these techniques has been previously described in
detail16–20 (Appendix 2).
856 United European Gastroenterology Journal 6(6)
 PCP visit













* Likert scales (from 0 to 5) about the






















Figure 1. Flowchart of the study procedures.
CD: coeliac disease; IEL: intraepithelial lymphocyte; IgA: immunoglobulin A; PCP: primary care physician; POCT: point-of-care test;
anti-tTG2: anti-transglutaminase 2 antibodies.
Table 1. Clinical enrolment criteria.
Unexplained anaemia (Hb <11.5 g/dl for women and <12 g/dl for men) or iron deficiency (serum ferritin <20 mg/l)a
Unexplained recurrent abdominal pain with bloating or flatulence (longer than four weeks)a
Unexplained isolated frequent abdominal bloating with flatulence (longer than four weeks)a
‘Irritable bowel syndrome – Rome III criteria’
Chronic or recurrent frequent diarrhoea (longer than four weeks)a
Unexplained weight loss (>10% of weight) (in the last six months)a
Unexplained isolated and persistent hypertransaminasemia (ALT/AST levels two times the normal range for at least six months)b
Thyroid disorders with positive autoantibodies
Autoimmune disorders (insulin-dependent type 1 diabetes, autoimmune hepatitis, Sjögren’s syndrome) with confirmed diagnosis at
secondary- or tertiary-level hospital
Total IgA deficiency (<0.3 mg/l)
Epilepsies resistant to pharmacological treatment or epilepsies with intracranial calcifications
Dermatitis herpetiformis
Unexplained osteopenia (Z score <2 SD)
Down syndrome and Turner syndrome
Family history positive for CD (first- and second-degree relatives)
aAn initial diagnostic work-up was conducted to rule out other, potentially more severe diseases responsible for symptoms such as colon cancer or
inflammatory bowel disease.
bViral, metabolic, neoplastic and autoimmune liver diseases were previously ruled out.
ALT: alanine transaminase; AST: aspartate transaminase; CD: coeliac disease; Hb: haemoglobin; IgA: immunoglobulin A.
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POCT
IgA anti-DGP, IgG anti-DGP, and total IgA analyses
are embedded in Simtomax (Augurix SA,
Switzerland). A detailed description of the development
of the device has been previously described.14,15 In the
test, secondary gold-conjugated antibodies bind to the
patient’s antibodies to form detectable complexes that
are captured by the test in lines A and B. The CT is the
control line. A CD-positive result is indicated by detec-
tion of both the CT and A lines (Figure 2(a)). IgA
deficiency is indicated by absence of the B line.
Definition of CD
CD was considered in patients with (a) positive IgA/
IgG tTG2/AEA and duodenal changes of the CD spec-
trum (from lymphocytic enteritis to atrophy), and
(b) negative IgA/IgG tTG2/AEA but duodenal atrophy
together with CD cytometric pattern plus positive
immunofluorescence (IF) staining of tTG2 IgA
deposits.19,21
Calculation of the costs
Costs of three diagnostic approaches based on POCT or
serology as screening for CD were calculated as follows:
(a) standard diagnosis: serology followed by endoscopy
in positive patients, (b) POCT followed by confirmatory
serology in positive POCT and endoscopy in
seropositive patients, and (c) POCT followed by endos-
copy in positive patients (Table A.1 in Appendix 3).
Statistical analysis
The prevalence of CD in the general adult population
detected by serological screening in our area is 0.28%
(1:357).22 CD prevalence in symptomatic patients and
in risk groups is estimated at 3% to 10%.5–9,22,23 If the
prevalence of CD was around 3%, a sample size of 350
patients would enable us to obtain a 95% confidence
interval (CI) with a precision of 1.8%.24
In order to ascertain whether the ‘educational pro-
gramme’ had an impact on the number of diagnoses, we
performed a post hoc analysis to compare the CD cases
in the study period with those diagnosed during the
previous 18 months and cases diagnosed by the non-
participant PCPs in the study period. The Z test was
used to compare proportions. Prevalence of CD (95%
CI) in different periods was calculated. The diagnostic
accuracy of the POCT was assessed by means of sensi-
tivity, specificity, positive predictive value (PPV), and
negative predictive value (NPV), and their 95% CIs,
taking CD cases as the gold standard.
Ethical considerations
This study was conducted according to the ethical
guidelines of the 1975 Declaration of Helsinki.
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Figure 2. (a) Point-of-care test (Simtomax). CT: control line; line A: IgA/IgG deamidated gliadin peptide; line B: total IgA. (b) Results of
the present study.
CD: coeliac disease; IgA: immunoglobulin A; IgG: immunoglobulin G.
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Ethical approval was obtained from the Hospital
Universitari Mutua Terrassa Ethical Committee on 25
February 2014, and all patients signed the informed
consent.
Results
A total of 350 patients (266 women; 42.1 0.9 years)
were consecutively recruited. Of these, 210 patients
(60%) had only one clinical manifestation of CD,
gastrointestinal symptoms being the most frequent,
accounting for more than 60% (Figure A.1 in
Appendix 4). The Simtomax POCT was positive in
29 patients (8.2%) (Figure 2(a) and (b)). In 23 cases,
the B line was lacking but IgA deficiency was ruled out
in all cases (lowest value¼ 0.41 g/l). Four of the 29
patients positive for Simtomax fulfilled the criteria
for CD. Three of them had atrophy and the remaining
patient had a Marsh 1 lesion. All of them had a com-
plete cytometric CD pattern, tTG2 IgA duodenal
deposits and good clinical, serological, and histological
response to a GFD (Table 2). Of the 25 patients with
false-positive POCT (7.1%, n¼ 350 patients), 10 (40%)
had some duodenal markers of potential CD. A
detailed description of these patients is shown in
Table 3.
In 25 additional patients with both negative POCT
and standard serology, a duodenal biopsy was per-
formed due to persistent symptoms (Figure 1). Five of
these patients (Table 4) had some duodenal markers of
potential CD.
No differences were found in the percentage of
potential CD markers between patients with negative
and positive POCTs, not fulfilling the criteria of CD (10
of 25 patients – 40% – with positive POCT and five of
25 patients – 20% – with negative POCT; p¼ 0.216).
Accuracy of the DGP antibody POCT compared
with standard serology
The four patients fulfilling the criteria of CD had a
positive POCT, but only three of them had positive
standard serology (tTG2 and AEA). None of the
patients with negative POCT fulfilled the diagnostic
criteria of CD. This resulted in a sensitivity of POCT
detecting CD of 100% (95% CI: 40–100%), a specifi-
city of 93% (95% CI: 89–95%), NPV 100% (95% CI:
98.5–100%) and PPV 14% (95% CI: 4.5–33%).
Cost-effectiveness analysis
The total costs of the three diagnostic strategies, the
detailed procedures and the number of cases diagnosed
with each diagnostic strategy are detailed in Figure 3.
The use of POCT followed by endoscopy and duodenal
biopsy in positive patients demonstrated the best cost-
effective result with a total cost of E7360.63 per diag-
nosed case (n¼ 4).
Prevalence of CD in the ‘case-finding’ and control
cohorts. The prevalence of CD in the case-finding
cohort was 1.14% (95% CI: 0.44–2.90), which repre-
sents 1:87. This figure is 3.8 times higher than that
observed in the general adult population in the same
geographical area by using a mass screening serological
strategy.21 During the previous 18 months before the
initiation of the case-finding programme (1 October
2012 to 31 March 2014), 1050 serum IgA tTG2 deter-
minations were performed and seven patients fulfilled
the diagnostic criteria of CD, disclosing a prevalence of
0.67% (95% CI: 0.33–1.37), which represents 1:149. Six
patients had atrophy and one patient had a Marsh 1
lesion. In the case-finding study using POCT, CD was
Table 2. Serological, genetic and duodenal markers of the four patients fulfilling the diagnostic criteria of coeliac disease.
POCT Genetics Serology Histology Cytometric pattern tTG2 IgA deposits Outcome






histological response to GFD






histological response to GFD













histological response to GFD
tTG2: anti-transglutaminase 2 antibodies; AEA: endomysial antibodies; GFD: gluten-free diet; HLA: human leucocyte antigen; TCR: T cell receptor.
Complete coeliac cytometric pattern: TCRgd> 8.5% and CD3– <10%.
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diagnosed 1.7 times more often than in the previous
period of time; however, differences were not statistic-
ally significant.
In addition, 24 PCPs that did not participate in the
study requested 624 standard serology tests to rule out
CD during the study period. Six out of the 624 patients
fulfilled the diagnostic criteria of CD (two with atro-
phy, four with Marsh 1). The prevalence of CD in this
cohort attended by PCPs not participating in the case-
finding study was 0.96% (95% CI: 0.44–2.08), repre-
senting 1:104.
Discussion
The present study showed better diagnostic accuracy
for a POCT based on IgA/IgG-DGP detection than
standard serology for CD diagnosis. However, the
low prevalence of CD in this case-finding cohort
means that the difference in favour of POCT was due
only to a single case diagnosed with POCT and not
with standard serology. Thus, it can be considered
that both serum IgA tTG2 and DGP-based POCTs
are good diagnostic tools for CD screening in primary
care. Similar diagnostic accuracy of both tests was
demonstrated in the pre-endoscopy setting.14,15
The low PPV (14%) of the POCT Simtomax was
due to the detection of 7% false-positive patients for
both CD diagnosis and IgA deficiency, suggesting that
the cut-off for IgA/IgG-DGP detection is very low,
ensuring that no cases of CD are missed. To ascertain
whether this false-positive IgA/IgG-DGP detected by
POCT could reflect a potential CD, the duodenal
Table 3. Genetic and duodenal markers of the 10 patients with positive POCT and negative standard serology (t-TG2, AEA) with duodenal
markers of potential CD.
POCT Genetics Serology Histology Cytometric pattern tTG2 IgA deposits Outcome





þþþ Good clinicala and histological
response to GFD
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– Non-response to GFD
Irritable bowel syndrome





þþ Crohn’s disease of the
small bowel





þþ Bile acid malabsorption













tAEA: endomysial antibodies; CD: coeliac disease; GFD: gluten-free diet; HLA: human leucocyte antigen; POCT: point-of-care test; TCR: T cell receptor;
TG2: anti-transglutaminase 2 antibodies.
Complete coeliac cytometric pattern: TCRgd> 8.5% and CD3–<10.
Incomplete coeliac cytometric pattern: selective increase of TCRgd> 8.5%.
aChronic relapsing diarrhoea.
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STANDARD DIAGNOSIS
t-TG2 + BIOPSY




































Figure 3. Total costs and detailed procedures of the three diagnostic strategies.
anti-tTG2: anti-transglutaminase 2 antibodies; POCT: point-of-care test. Tariffs of the National Health Services of the Catalan Government
are provided in Table A.1 (Appendix 3).
Table 4. Genetic and duodenal markers of potential CD of the five patients with negative POCT and negative standard serology (t-TG2,
AEA).
POCT Genetics Serology Histology Cytometric pattern tTG2 IgA deposits Outcome













– Good clinicalb/histological response to GFD













þþ Non-response to GFD Fructose/
sorbitol intolerance





þþ Non-response to GFD
Bile acid malabsorption
AEA: endomysial antibodies; CD: coeliac disease; GFD: gluten-free diet; HLA: human leucocyte antigen; POCT: point-of-care test; TCR: T cell receptor; tTG2:
anti-transglutaminase 2 antibodies.
Complete coeliac cytometric pattern: TCRgd> 8.5% and CD3– <10.
Incomplete coeliac cytometric pattern: selective increase of TCRgd> 8.5%.
aRelapsing diarrhoea. bRelapsing diarrhoeaþ iron-deficient anaemia.
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biopsy was analysed not only for histopathology but
also for IEL subsets (T cell receptor (TCR) gdþ and
CD3–) and tTG2 IgA deposits.19 Though the majority
of false-positive patients had normal duodenal mucosa,
40% of them had duodenal markers of potential CD.
However, similar results were obtained in a subgroup of
25 patients with negative POCTs and persistent symp-
toms in whom a duodenal biopsy was performed.
Therefore, we realized that the majority of these
patients did not have CD.
It is remarkable that some symptomatic patients
may have a seronegative ‘coeliac-lite’ disease and may
benefit from a GFD.25 This was the case for two
patients in the POCT-negative and two more in the
POCT-positive group showing a good response to a
GFD. In seronegative patients with a doubtful diagno-
sis of CD, the performance of a duodenal biopsy is
mandatory. In these cases, the presence of duodenal
CD markers together with positive genetic predispos-
ition and histological lesion of the CD spectrum (either
lymphocytic enteritis or atrophy) could be of help in
deciding whether to start a GFD.19,25 Regardless,
POCT based on IgA/IgG-DGP has no more accuracy
for ‘coeliac-lite’ diagnosis than IgA tTG2.
The strategy of using the Simtomax POCT for CD
screening was more cost effective than a strategy based
on tTG2 according to the tariffs of the National Health
Services of the Catalan government. The immediate
referral of the patients with positive POCT to the
Endoscopic Unit for duodenal biopsy allowed us to
reduce the time delay from the visit of the PCP to
CD diagnosis. In addition, the POCT strategy allowed
us to reduce the cost per patient to almost half com-
pared with the cost using standard serology, even
though 7% more patients in the POCT group than in
the standard diagnosis had to undergo duodenal
biopsy. However, it should be taken into account that
prices may vary among countries, organisation of
healthcare institutions and/or insurance companies.
The study also demonstrated that the case-finding
strategy using a IgA/IgG-DGP POCT in patients at
risk for CD is suitable for CD diagnosis in primary
care since it allowed for the detection of four times as
many cases of CD (1:87 (1.14%)) than that found in the
general population of the same area (1:357 (0.28%)).22
The post hoc analysis to assess the impact of the
‘educational programme’ on the number of diagnoses
showed that PCPs participating in the POCT study
diagnosed 1.7 more CD cases than those diagnosed in
the previous 18-month period. Differences were not
statistically significant but the sample size was not cal-
culated to find differences between the two periods. In
fact, taking into account the CD prevalence in our geo-
graphical area, more than 2000 patients per group
would be needed to find differences.
The 0.96% prevalence of CD in the cohort attended
by PCPs not participating in the case-finding study
(using tTG2 for screening) was intermediate between
those found in the POCT study (1.14%) and in the
previous period (0.67%). Therefore, it seems that
PCPs’ declining participation was also influenced by
the ‘educational programme’ and by the active CD
findings developed by their colleagues. A similar posi-
tive influence of an active CD case-finding environment
was previously demonstrated by an Italian case-finding
study in primary care.6
The prevalence of CD in other case-finding studies
using standard serology for CD screening ranged from
2% to 10%, a figure higher than in our study. However,
in these geographical areas the prevalence of CD in the
general population was 1:100, which is clearly higher
than that reported in our country.5–9,16 Thus, the preva-
lence of CD in high-risk groups essentially depends on
the prevalence of CD in a specific geographical area, as
well as on the type of risk group included. In this sense,
first-degree relatives have the highest risk of CD10,23
while patients with only one digestive symptom have
the lowest CD risk.9 In our study, the most frequent
inclusion criteria were digestive symptoms, which
accounted for 60% of the total cohort; the majority
of them had only one digestive symptom.
The present study has some limitations. The most
important is the use of tTGA as the main parameter
for CD diagnosis. The availability of duodenal histo-
pathology in all the patients would be desirable in
future studies. This would provide valuable informa-
tion deeper in the CD iceberg in seronegative patients.
Another limitation is the number of included patients,
which precluded establishing firm conclusions regard-
ing the impact of the ‘educational programme’ on the
number of new CD diagnoses between periods. At any
rate, a POCT detection was demonstrated to be suitable
for CD screening in primary care. POCT identified all
seropositive patients while a negative test ruled out CD.
It is easy to use, allows early diagnosis, and is cost
effective compared with the standard approach using
serology.
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Appendix 2
Analytical methods
Serology. Serology was analysed in the laboratory of the
health area (CATLAB, Terrassa). IgA tTG2 (or IgG
tTG2 in IgA deficiency) were assessed by enzyme-
linked immunosorbent assay detection (kit EliA
CelikeyTM, Phadia AB, Freiburg, Germany). AEA
was performed by indirect immunofluorescence assay
in serum samples at 1:5 dilution (commercial sections
of monkey distal oesophagus; BioMedical Diagnostics,
Marne-la-Vallée, France) in all patients with positive
POCT and/or positive tTG2.
Histopathological assessment. Four endoscopic biopsies
from the duodenum were processed with hematoxylin/
eosin staining and CD3 immunophenotyping.
Histopathological findings were classified following the
revised Marsh criteria.16 Lymphocytic enteritis (Marsh
1) was defined as 25 IEL per 100 epithelial nuclei.17,18
Flow cytometry and intestinal deposits of anti-TG2 IgA
antibodies. A description of both techniques has pre-
viously been presented in detail by our research
group.19 The incomplete CD pattern consists of a selec-
tive increase of TCRgdþ >8.5%. IgA tTG2 deposits
were analysed with IF staining using a confocal
microscope. Both the complete cytometric pattern and
the sum of an incomplete cytometric pattern with posi-
tive tTG2 IgA deposits have 100% specificity for CD
diagnosis.19
CD genetic markers. Genomic DNA from whole blood
was purified using a commercial QiampDNABlood
Mini kit (Qiagen, Düsseldorf, Germany). A commercial
reverse hybridisation kit for the detection of CD het-
erodimers HLA-DQ2 (A1*0501/*0505, B1*0201/
*0202) and HLA-DQ8 (A1*0301, B1*0302) was used
(GenID, GmbH, Strasburg, Germany). HLA-DQ2/
DQ8 haplotypes are present in 97% of CD patients in
our geographical area.20 Positive coeliac genetics indi-
cates the presence of HLA-DQ2.5, HLA-DQ2.2 and/ or
HLA-DQ8.
Appendix 3
Table A.1 Tariffs of the National Health Services
of the Catalan government
Primary care physician visit 41.00 E
Blood analysis (total) 27,88 E
- IgA tTG2 12.43 E
- IgA 6.45 E
- Blood collection (nurseþ expendables) 9.00 E
AEA (confirmatory serology) 13.88 E
Esophagogastroduodenoscopyþ biopsyþ sedationa 130.3 E
Histopathological analysis (2 to 10 paraffin blocks) 43.00 E
POCT procedure 28.00 E
- Simtomax device 20.00E
- Nurse reading 8.00 E
tAEA: endomysial antibodies; IgA: immunoglobulin A; IgG: immunoglobu-
lin G; POCT: point-of-care test; TCR: Toll cell receptor;TG2: anti-transgluta-
minase 2 antibodies.
National Health Services of the Catalan government (DOGC núm. 6079
2-3-2012. Review 2013-Resolution SLT/353/2013).
aRecommended tariffs of the Official College of Physicians of Barcelona.
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Appendix 4
Figure A1. Frequency of the clinical enrollment criteria.
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